Exagen (XGN) Competitors

Celcuity (NASDAQ:CELC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.

Which has better valuation and earnings, CELC or XGN?

Exagen has higher revenue and earnings than Celcuity. Exagen is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$63.78M	-$3.03	-3.50
Exagen	$56.72M	2.17	-$23.69M	-$0.84	-6.87

Does the MarketBeat Community believe in CELC or XGN?

Celcuity received 315 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 67.92% of users gave Celcuity an outperform vote while only 62.22% of users gave Exagen an outperform vote.

Company	Underperform	Outperform
Celcuity	Outperform Votes 343 67.92%	Underperform Votes 162 32.08%
Exagen	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%

Do insiders and institutionals hold more shares of CELC or XGN?

63.3% of Celcuity shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 15.8% of Celcuity shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate CELC or XGN?

Celcuity presently has a consensus price target of $30.80, indicating a potential upside of 190.57%. Exagen has a consensus price target of $7.50, indicating a potential upside of 29.98%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Exagen	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, CELC or XGN?

Celcuity has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Does the media prefer CELC or XGN?

In the previous week, Celcuity had 7 more articles in the media than Exagen. MarketBeat recorded 17 mentions for Celcuity and 10 mentions for Exagen. Celcuity's average media sentiment score of 0.90 beat Exagen's score of -0.08 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Exagen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is CELC or XGN more profitable?

Celcuity has a net margin of 0.00% compared to Exagen's net margin of -30.36%. Celcuity's return on equity of -62.66% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-62.66%	-39.78%
Exagen	-30.36%	-92.58%	-33.74%

Summary

Celcuity beats Exagen on 11 of the 17 factors compared between the two stocks.